Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma

Research output: Contribution to journal › Article › peer-review

Standard

Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. / Mead, Ben; Hill, Lisa J; Blanch, Richard J; Ward, Kelly; Logan, Ann; Berry, Martin; Leadbeater, Wendy; Scheven, Ben A.

In: Cytotherapy, Vol. 18, No. 4, 04.2016, p. 487-496.

Research output: Contribution to journal › Article › peer-review

Harvard

Mead, B, Hill, LJ, Blanch, RJ, Ward, K, Logan, A, Berry, M, Leadbeater, W & Scheven, BA 2016, 'Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma', Cytotherapy, vol. 18, no. 4, pp. 487-496. https://doi.org/10.1016/j.jcyt.2015.12.002

APA

Mead, B., Hill, L. J., Blanch, R. J., Ward, K., Logan, A., Berry, M., Leadbeater, W., & Scheven, B. A. (2016). Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. Cytotherapy, 18(4), 487-496. https://doi.org/10.1016/j.jcyt.2015.12.002

Vancouver

Mead B, Hill LJ, Blanch RJ, Ward K, Logan A, Berry M et al. Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. Cytotherapy. 2016 Apr;18(4):487-496. https://doi.org/10.1016/j.jcyt.2015.12.002

Author

Mead, Ben ; Hill, Lisa J ; Blanch, Richard J ; Ward, Kelly ; Logan, Ann ; Berry, Martin ; Leadbeater, Wendy ; Scheven, Ben A. / Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. In: Cytotherapy. 2016 ; Vol. 18, No. 4. pp. 487-496.

Bibtex

@article{aa07e800e5c2473fa42685ea978c87c5,
title = "Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma",
abstract = "BACKGROUND AIMS: Glaucoma is a leading cause of irreversible blindness involving loss of retinal ganglion cells (RGC). Mesenchymal stromal cells (MSC) have shown promise as a paracrine-mediated therapy for compromised neurons. It is, however, unknown whether dental pulp stem cells (DPSC) are effective as a cellular therapy in glaucoma and how their hypothesized influence compares with other more widely researched MSC sources. The present study aimed to compare the efficacy of adipose-derived stem cells, bone marrow-derived MSC (BMSC) and DPSC in preventing the loss of RGC and visual function when transplanted into the vitreous of glaucomatous rodent eyes.METHODS: Thirty-five days after raised intraocular pressure (IOP) and intravitreal stem cell transplantation, Brn3a(+) RGC numbers, retinal nerve fibre layer thickness (RNFL) and RGC function were evaluated by immunohistochemistry, optical coherence tomography and electroretinography, respectively.RESULTS: Control glaucomatous eyes that were sham-treated with heat-killed DPSC had a significant loss of RGC numbers, RNFL thickness and function compared with intact eyes. BMSC and, to a greater extent, DPSC provided significant protection from RGC loss and RNFL thinning and preserved RGC function.DISCUSSION: The study supports the use of DPSC as a neuroprotective cellular therapy in retinal degenerative disease such as glaucoma.",
keywords = "dental pulp stem cells, glaucoma, stem cell transplantation, mesenchymal stromal cells, neuroprotection, retinal ganglion cells",
author = "Ben Mead and Hill, {Lisa J} and Blanch, {Richard J} and Kelly Ward and Ann Logan and Martin Berry and Wendy Leadbeater and Scheven, {Ben A}",
note = "Copyright {\textcopyright} 2016 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.",
year = "2016",
month = apr,
doi = "10.1016/j.jcyt.2015.12.002",
language = "English",
volume = "18",
pages = "487--496",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Elsevier",
number = "4",

}

RIS

TY - JOUR

T1 - Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma

AU - Mead, Ben

AU - Hill, Lisa J

AU - Blanch, Richard J

AU - Ward, Kelly

AU - Logan, Ann

AU - Berry, Martin

AU - Leadbeater, Wendy

AU - Scheven, Ben A

N1 - Copyright © 2016 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

PY - 2016/4

Y1 - 2016/4

N2 - BACKGROUND AIMS: Glaucoma is a leading cause of irreversible blindness involving loss of retinal ganglion cells (RGC). Mesenchymal stromal cells (MSC) have shown promise as a paracrine-mediated therapy for compromised neurons. It is, however, unknown whether dental pulp stem cells (DPSC) are effective as a cellular therapy in glaucoma and how their hypothesized influence compares with other more widely researched MSC sources. The present study aimed to compare the efficacy of adipose-derived stem cells, bone marrow-derived MSC (BMSC) and DPSC in preventing the loss of RGC and visual function when transplanted into the vitreous of glaucomatous rodent eyes.METHODS: Thirty-five days after raised intraocular pressure (IOP) and intravitreal stem cell transplantation, Brn3a(+) RGC numbers, retinal nerve fibre layer thickness (RNFL) and RGC function were evaluated by immunohistochemistry, optical coherence tomography and electroretinography, respectively.RESULTS: Control glaucomatous eyes that were sham-treated with heat-killed DPSC had a significant loss of RGC numbers, RNFL thickness and function compared with intact eyes. BMSC and, to a greater extent, DPSC provided significant protection from RGC loss and RNFL thinning and preserved RGC function.DISCUSSION: The study supports the use of DPSC as a neuroprotective cellular therapy in retinal degenerative disease such as glaucoma.

AB - BACKGROUND AIMS: Glaucoma is a leading cause of irreversible blindness involving loss of retinal ganglion cells (RGC). Mesenchymal stromal cells (MSC) have shown promise as a paracrine-mediated therapy for compromised neurons. It is, however, unknown whether dental pulp stem cells (DPSC) are effective as a cellular therapy in glaucoma and how their hypothesized influence compares with other more widely researched MSC sources. The present study aimed to compare the efficacy of adipose-derived stem cells, bone marrow-derived MSC (BMSC) and DPSC in preventing the loss of RGC and visual function when transplanted into the vitreous of glaucomatous rodent eyes.METHODS: Thirty-five days after raised intraocular pressure (IOP) and intravitreal stem cell transplantation, Brn3a(+) RGC numbers, retinal nerve fibre layer thickness (RNFL) and RGC function were evaluated by immunohistochemistry, optical coherence tomography and electroretinography, respectively.RESULTS: Control glaucomatous eyes that were sham-treated with heat-killed DPSC had a significant loss of RGC numbers, RNFL thickness and function compared with intact eyes. BMSC and, to a greater extent, DPSC provided significant protection from RGC loss and RNFL thinning and preserved RGC function.DISCUSSION: The study supports the use of DPSC as a neuroprotective cellular therapy in retinal degenerative disease such as glaucoma.

KW - dental pulp stem cells

KW - glaucoma

KW - stem cell transplantation

KW - mesenchymal stromal cells

KW - neuroprotection

KW - retinal ganglion cells

U2 - 10.1016/j.jcyt.2015.12.002

DO - 10.1016/j.jcyt.2015.12.002

M3 - Article

C2 - 26897559

VL - 18

SP - 487

EP - 496

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 4

ER -